The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients

Journal of Clinical Psychiatry

Volumn 69, Issue 12, 2008, Pages 1880-1886

  Brunnauer, Alexander ^a,c   Laux, Gerd ^a,b   David, Irmgard ^a   Fric, Mirijam ^a   Hermisson, Igor ^b   Möller, Hans Jürgen ^b  

^a Academic Hospital of Psychiatry Psychotherapy and Neurology   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Inn Salzach Klinikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE; REBOXETINE;

ADULT; ALERTNESS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRIVING ABILITY; DRUG EFFECT; FEMALE; HUMAN; MALE; MENTAL CONCENTRATION; MENTAL DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SIMULATION; STRESS; TRAFFIC SAFETY; VISION;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ATTENTION; AUTOMOBILE DRIVING; COMPUTER SIMULATION; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; MORPHOLINES; PERSONALITY INVENTORY; PSYCHOMOTOR PERFORMANCE; REACTION TIME;

EID: 60349088688     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n1205     Document Type: Article

References (28)

1. Vaa T. Impairments, diseases, age and their relative risks of accident involvement: results from a meta-analysis. Deliverable R1.1 from EU-project IMMORTAL: TØI report 690. Oslo, Norway: Institute of Transport Economics; 2003:1-48. Available at: http://www.immortal.or.at/deliverables.php#R1.1. Accessed Aug 21, 2008
2. Austin MP, Mitchel P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001;178:200-206
3. Sabbe B, Hulstijn W. Psychomotor disturbances in schizophrenia and depressive disorders. Curr Opin Psychiatry 2001;14:597-603
4. Zihl J, Grön G, Brunnauer A. Cognitive deficits in schizophrenia and affective disorder: evidence for a final common pathway disorder. Acta Psychiatr Scand 1998;97:351-357
5. Ray WA, Fought WL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992;136:873-883
6. Möller HJ. Are all antidepressants the same? J Clin Psychiatry 2000;61(suppl 6):24-28
7. Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003;64:20-29
8. Laux G. Psychiatric illness and driving ability: an overview. Nervenarzt 2002;73:231-238
9. Brunnauer A, Laux G. Antidepressants and driving ability. Psychiatr Prax 2003;30:102-105
10. Brunnauer A, Laux G, Geiger E, et al. Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry 2006;67(11):1776-1781
11. Grabe HJ, Wolf T, Grätz S, et al. The influence of polypharmacological antidepressive treatment on central nervous information processing of depressed patients: implications for fitness to drive. Neuropsychobiology 1998;37:200-204
12. Wingen M, Ramaekers JG, Schmitt JA. Driving impairment in depressed patients receiving long-term antidepressant treatment. Psychopharmacology (Berl) 2006;188:84-91
13. Bundesanstalt für Strassenwesen (Hrsg.). Begutachtungs-Leitlinien zur Kraftfahrereignung. Schriftenreihe der bast, Heft M 115. Wirtschaftsverlag Bremerhaven; 2000
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
15. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
16. Kisser R, Wenninger U. Computerunterstütztes Testen im Rahmen der Fahreignungsuntersuchung (Act & React Testsystem ART-90). Kleine Fachbuchreihe des Kuratoriums für Verkehrssicherheit. Wien, Austria: Kuratorium für Verkehrssicherheit; 1983
17. Schuhfried G. Wiener Testsystem (Vienna Test System). Mödling, Austria: Dr. Gernot Schuhfried GmbH; 2000
18. Bukasa B, Christ R, Pocorny-Seliger E, et al. Validitätsprüfung verkehrspsychologischer Leistungstests für die Fahreignungsbegutachtung. Z Verkehrssicherheit 2003;49:191-197
19. Karner T, Biehl B. Über die Zusammenhänge verschiedener Versionen von Leistungstests im Rahmen der Verkehrspsychologischen Diagnostik. Z Verkehrssicherheit 2001;42:53-63
20. Weiland-Fiedler P, Erickson K, Waldeck T, et al. Evidence for continuing neuropsychological impairments in depression. J Affect Disord 2004;82:253-258
21. Herberg KW. Traffic safety and everyday safety after intake of citalopram: an analysis of the effect of a 14-day treatment with the dose 20mg/d on safety relevant performance. Psychopharmakotherapie 2001;18:81-88
22. Ridout F, Hindmarch I. Effects of tianeptine and mianserin on car driving skills. Psychopharmacology (Berl) 2001;154:356-361
23. Ridout F, Meadows R, Johnsen S, et al. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 2003;18(4):261-269
24. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005;66(4):436-443
25. Hindmarch I. Effect of antidepressants on cognitive and psychomotor function: the lack of effect of reboxetine. Hum Psychopharmacol 1998;13:21-27
26. Siepmann M, Muck-Weymann M, Joraschky P, et al. The effects of reboxetine on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl) 2001;157(2):202-207
27. Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 2003;18:9-14
28. Ramaekers JG, Muntjewerff ND, Van Veggel LMA, et al. Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Hum Psychopharmacol 1998;13:S87-S97